Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-EVEREST: REGN7508 vs Apixaban in Atrial Fibrillation
NCT07626411Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Countries
- 3
01
Overview
A Phase 3 trial of REGN7508 in Atrial fibrillation (AFib), sponsored by Regeneron Pharmaceuticals. Started Aug 2026; status: recruiting.
02
Drugs
REGN7508
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07626411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07626411.